NEW YORK (
CHANGE IN RATINGS
was upgraded at Wells Fargo to outperform from market perform. Stock has underperformed over the past four months, but Wells Fargo said it recently had a constructive meeting with management.
(BBRY - Get Report)
was downgraded at Jefferies to hold from buy. $8 price target. Sub scale handset business undercuts MDM opportunity, Jefferies said.
Blackberry was upgraded at Credit Suisse to neutral from underperform. $8 price target. Estimates slashed, but risks appear fully reflected in the stock, Credit Suisse said.
was downgraded at BMO Capital to underperform from market perform. $28 price target. Margins could be hurt, as the company invests more in the business, BMO Capital said.
was downgraded at Credit Suisse to neutral from outperform. $68 price target. Company is facing another transition year in 2015, Credit Suisse said.
was upgraded to buy.
was downgraded at Morgan Stanley to market perform from outperform. Company trades at a premium to its peers and growth is maturing, Morgan Stanley said.
(DDD - Get Report)
was initiated with a buy rating at Bank of America/Merrill Lynch. $65 price target. Market should continue to grow over the coming quarters, BofA/Merrill said.
(DWA - Get Report)
was downgraded at B. Riley to neutral from buy. Valuation call, as the stock is up 55% over the past five months, B. Riley said.
(EVHC - Get Report)
was initiated with a neutral rating at Goldman Sachs. Valuation call, based on a $26 price target, Goldman Sachs said.
Envision Healthcare was initiated with a buy rating and $32 price target at UBS. Accelerated growth will come from health reform and its increased exposure to outsourced physician services, UBS said.
was upgraded to buy at TheStreet Ratings.
was downgraded at Jefferies to hold from buy. $80 price target. Valuation call, said Jefferies.
was upgraded at Bank of America/Merrill Lynch to neutral from underperform. $15 price target. Company should benefit from better domestic pricing, BofA/Merrill said.